ALLERGIC RHINITIS ENVIRONMENTAL TRIGGERS ANDLONG-TERM MANAGEMENT STRATEGIES
Main Article Content
Keywords
allergies, management, immunotherapy, pharmacotherapy
Abstract
Background: Allergic rhinitis is a fairly widespread disease that occurs in reaction to the presence of
allergens in the air like pollen, dust mites and animal hair. It can mainly affect the quality of life in
the communities thereby causing symptoms including sneezing, nasal blockage and itchiness.
Objectives: To determine the degree of success of differents long-term treatment approaches used in
the management of allergic rhinitis on symptoms and quality of life of the patients.
Study design : A cross-sectional study.
Place and duration of study . department of ENT kabir medical college from jan 2021 to july 2021
Methods: A cross sectional survey was also conducted on 150 patients with allergic rhinitis.
Treatment allocation was also random involving various management approaches such as avoidance,
medications and immunization. The difference in severity of the symptoms and the quality of life
were measured with standardised questionnaires at baseline as well as after 6 months.
Results: Of 150 patients 72 of them were using both pharmacotherapy and immunotherapy and were having higher mean symptom improvement of 45% (p < 0. 001 SD = 6. 4). Fifty percent of each of the allergen avoidance group (p < 0. 05, SD = 5. 8) and the pharmacotherapy-only group (p < 0. 05,
SD = 7. 2) displayed an improvement in their number of asthmatic events.
Conclusion: the treatment options of pharmacotherapy and immunotherapy are the most effective
long-term control options for allergic rhinitis. Exposure restrictions also have their role especially in
regard to patients with specific allergen sensitivities.
References
2. Pawankar R. Allergic rhinitis and asthma: are they manifestations of one syndrome? Clin Exp Allergy. 2006;36(1):1-4
3. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2).
4. D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007;62(9):976-990.
5. Calderon MA, Demoly P, Gerth van Wijk R, et al. Allergic Rhinitis and its Impact on Asthma: Revision of ARIA guidelines. J Allergy Clin Immunol. 2014;134(5):1027-1037.
6. Custovic A, Simpson A, Murray CS, et al. The national allergy strategy group (NASG) guidelines for the diagnosis and management of allergic rhinitis. Prim Care Respir J. 2010;19(3):217-222.
7. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476
8. Canonica GW, Bousquet J, Mullol J, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
9. Scadding GK, Kariyawasam HH, Scadding GW. Allergic rhinitis. In: Adkinson NF Jr, Bochner BS, Burks AW, et al., eds. Middleton's Allergy: Principles and Practice. 8th ed. Elsevier Saunders; 2014:937-955
10. Passalacqua G, Bousquet J, Carlsen KH, et al. ARIA update: I—Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006;117(5):1054-1062.
11. Custovic A, Simpson A, Murray CS, et al. The national allergy strategy group (NASG) guidelines for the diagnosis and management of allergic rhinitis. Prim Care Respir J. 2010;19(3):217-222.
12. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2).
13. Canonica GW, Bousquet J, Mullol J, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
14. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562.
15. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476.